JP2010120964A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010120964A5 JP2010120964A5 JP2010036052A JP2010036052A JP2010120964A5 JP 2010120964 A5 JP2010120964 A5 JP 2010120964A5 JP 2010036052 A JP2010036052 A JP 2010036052A JP 2010036052 A JP2010036052 A JP 2010036052A JP 2010120964 A5 JP2010120964 A5 JP 2010120964A5
- Authority
- JP
- Japan
- Prior art keywords
- preparation
- growth factor
- methylideneaminooxy
- dihydronaphthalen
- biodegradation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003795 chemical substances by application Substances 0.000 claims 5
- 102000003745 Hepatocyte Growth Factor Human genes 0.000 claims 4
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 claims 4
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims 4
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 4
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 4
- 206010002383 Angina Pectoris Diseases 0.000 claims 3
- 238000006065 biodegradation reaction Methods 0.000 claims 3
- 208000010125 myocardial infarction Diseases 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 239000004480 active ingredient Substances 0.000 claims 2
- 239000003405 delayed action preparation Substances 0.000 claims 2
- 229920001002 functional polymer Polymers 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 239000004005 microsphere Substances 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 1
- 230000005923 long-lasting effect Effects 0.000 claims 1
- 229920000642 polymer Polymers 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000000069 prophylactic effect Effects 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2010036052A JP5287761B2 (ja) | 2002-10-10 | 2010-02-22 | 内因性修復因子産生促進剤 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2002298079 | 2002-10-10 | ||
| JP2002298079 | 2002-10-10 | ||
| JP2002318830 | 2002-10-31 | ||
| JP2002318830 | 2002-10-31 | ||
| JP2003117604 | 2003-04-22 | ||
| JP2003117604 | 2003-04-22 | ||
| JP2010036052A JP5287761B2 (ja) | 2002-10-10 | 2010-02-22 | 内因性修復因子産生促進剤 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2005501023A Division JP4497320B2 (ja) | 2002-10-10 | 2003-10-09 | 内因性修復因子産生促進剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010120964A JP2010120964A (ja) | 2010-06-03 |
| JP2010120964A5 true JP2010120964A5 (https=) | 2010-07-15 |
| JP5287761B2 JP5287761B2 (ja) | 2013-09-11 |
Family
ID=32096713
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2005501023A Expired - Fee Related JP4497320B2 (ja) | 2002-10-10 | 2003-10-09 | 内因性修復因子産生促進剤 |
| JP2010036052A Expired - Fee Related JP5287761B2 (ja) | 2002-10-10 | 2010-02-22 | 内因性修復因子産生促進剤 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2005501023A Expired - Fee Related JP4497320B2 (ja) | 2002-10-10 | 2003-10-09 | 内因性修復因子産生促進剤 |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US7547715B2 (https=) |
| EP (2) | EP2465537B1 (https=) |
| JP (2) | JP4497320B2 (https=) |
| AU (1) | AU2003272963A1 (https=) |
| DK (2) | DK1563846T3 (https=) |
| ES (2) | ES2584606T3 (https=) |
| HU (1) | HUE029417T2 (https=) |
| PT (2) | PT2465537T (https=) |
| TW (1) | TW200413000A (https=) |
| WO (1) | WO2004032965A1 (https=) |
Families Citing this family (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2584606T3 (es) | 2002-10-10 | 2016-09-28 | Ono Pharmaceutical Co., Ltd. | Microesferas que comprenden ONO-1301 |
| WO2005072743A1 (ja) * | 2004-01-30 | 2005-08-11 | Ono Pharmaceutical Co., Ltd. | 気管支拡張剤 |
| US7473678B2 (en) | 2004-10-14 | 2009-01-06 | Biomimetic Therapeutics, Inc. | Platelet-derived growth factor compositions and methods of use thereof |
| US8114841B2 (en) | 2004-10-14 | 2012-02-14 | Biomimetic Therapeutics, Inc. | Maxillofacial bone augmentation using rhPDGF-BB and a biocompatible matrix |
| JP4775663B2 (ja) * | 2005-03-30 | 2011-09-21 | 地方独立行政法人 大阪府立病院機構 | 血管新生制御方法 |
| US9422521B2 (en) * | 2005-09-12 | 2016-08-23 | Es Cell International Pte Ltd. | Differentiation of pluripotent stem cells with a kinase inhibitor or PGI2 |
| ES2427993T3 (es) | 2006-02-09 | 2013-11-05 | Biomimetic Therapeutics, Llc | Composiciones y métodos para el tratamiento de hueso |
| EP3424507A1 (en) | 2006-03-24 | 2019-01-09 | Children's Medical Center Corporation | Method to modulate hematopoietic stem cell growth |
| US9161967B2 (en) | 2006-06-30 | 2015-10-20 | Biomimetic Therapeutics, Llc | Compositions and methods for treating the vertebral column |
| CA2656278C (en) | 2006-06-30 | 2016-02-09 | Biomimetic Therapeutics, Inc. | Compositions and methods for treating rotator cuff injuries |
| US20080171972A1 (en) * | 2006-10-06 | 2008-07-17 | Stopek Joshua B | Medical device package |
| ES2459743T3 (es) * | 2006-10-19 | 2014-05-12 | Ono Pharmaceutical Co., Ltd. | Preparación de liberación sostenida para terapia de regeneración tisular |
| AU2013213727B2 (en) * | 2006-10-20 | 2016-03-17 | Children's Medical Center Corporation | Method to enhance tissue regeneration |
| EP2679221B1 (en) | 2006-10-20 | 2020-09-23 | Children's Medical Center Corporation | Method to enhance tissue regeneration |
| US8410171B2 (en) * | 2006-10-26 | 2013-04-02 | Ono Pharmaceutical Co., Ltd. | Adhesive preparation |
| US8106008B2 (en) | 2006-11-03 | 2012-01-31 | Biomimetic Therapeutics, Inc. | Compositions and methods for arthrodetic procedures |
| WO2008058766A1 (en) * | 2006-11-16 | 2008-05-22 | Bayer Schering Pharma Aktiengesellschaft | Ep2 and ep4 agonists as agents for the treatment of influenza a viral infection |
| JP2008195660A (ja) * | 2007-02-14 | 2008-08-28 | Kitasato Institute | 中枢循環改善薬 |
| EP2259807B1 (en) | 2008-02-07 | 2013-04-24 | Biomimetic Therapeutics, Inc. | Compositions for distraction osteogenesis |
| EP2135607A1 (en) | 2008-06-18 | 2009-12-23 | Pharnext | Combination of pilocarpin and methimazol for treating Charcot-MarieTooth disease and related disorders |
| HUE025885T2 (en) * | 2008-06-23 | 2016-05-30 | Nippon Shinyaku Co Ltd | Therapeutic agent for the treatment of spinal constriction |
| KR20110067035A (ko) | 2008-09-09 | 2011-06-20 | 바이오미메틱 세라퓨틱스, 인크. | 건 및 인대 손상의 치료를 위한 혈소판-유래 성장 인자 조성물 및 방법 |
| WO2010091052A2 (en) | 2009-02-03 | 2010-08-12 | Children's Medical Center Corporation | Methods for enhancing hematopoietic stem/progenitor cell engraftment |
| WO2010096264A2 (en) | 2009-02-03 | 2010-08-26 | Children's Medical Center Corporation | Methods for enhancing hematopoietic stem/progenitor cell engraftment |
| US20100267826A1 (en) | 2009-04-20 | 2010-10-21 | The Board Of Trustees Of The Leland Stanford Junior University | Treatment of ischemic episodes and cerebroprotection through Prostaglandin E2 (PGE2) EP2 and/or EP4 receptor agonists |
| US8569279B2 (en) | 2009-05-27 | 2013-10-29 | Sucampo Ag | Method for modulating claudin mediated functions |
| AU2010253720A1 (en) * | 2009-05-27 | 2011-12-08 | Osaka University | Pharmaceutical composition comprising prostaglandin derivatives for use in modulating claudin mediated functions and in the treatment of dermatological disorders |
| HUE032426T2 (en) * | 2009-05-27 | 2017-09-28 | Alkermes Pharma Ireland Ltd | Inhibition of flake aggregation in nanoparticulate meloxicam formulations |
| EP2322163A1 (en) * | 2009-11-03 | 2011-05-18 | Pharnext | New therapeutics approaches for treating alzheimer disease |
| US9387206B2 (en) | 2009-11-03 | 2016-07-12 | Pharnext | Therapeutic approaches for treating Alzheimer's disease |
| CN102811622A (zh) | 2010-02-22 | 2012-12-05 | 生物模拟治疗公司 | 用于治疗腱病的血小板衍生生长因子组合物和方法 |
| KR20130130694A (ko) * | 2010-07-30 | 2013-12-02 | 알러간, 인코포레이티드 | 피부 재생을 위한 화합물과 방법 |
| US20120142684A1 (en) * | 2010-12-02 | 2012-06-07 | Allergan, Inc. | Compounds and methods for skin repair |
| EP2675491A2 (en) * | 2011-02-17 | 2013-12-25 | Allergan, Inc. | Compositions and improved soft tissue replacement methods |
| EP2678022A2 (en) * | 2011-02-23 | 2014-01-01 | Allergan, Inc. | Compositions and improved soft tissue replacement methods |
| TR201809351T4 (tr) | 2011-03-01 | 2018-07-23 | Pharnext | Nörolojik bozuklukların baklofen ve akamprosat tabanlı terapisi. |
| US9241933B2 (en) | 2011-03-01 | 2016-01-26 | Pharnext | Compositions for treating amyotrophic lateral sclerosis |
| US9248111B2 (en) | 2011-03-01 | 2016-02-02 | Pharnext | Therapeutic approaches for treating parkinson's disease |
| US10010515B2 (en) | 2011-03-01 | 2018-07-03 | Pharnext | Therapeutic approaches for treating Parkinson's disease |
| US10111907B2 (en) | 2011-12-02 | 2018-10-30 | Fate Therapeutics, Inc. | Methods of treating ischemia |
| EP3785767A1 (en) | 2011-12-02 | 2021-03-03 | Fate Therapeutics, Inc. | Enhanced stem cell composition |
| WO2014046065A1 (ja) | 2012-09-21 | 2014-03-27 | 国立大学法人大阪大学 | 心筋・血管再生デバイスとしての重症心不全治療材 |
| ES2733998T3 (es) * | 2012-10-29 | 2019-12-03 | Cardio Incorporated | Agente terapéutico específico de enfermedad pulmonar |
| CA2890034A1 (en) * | 2012-11-16 | 2014-05-22 | Allergan, Inc. | Skin wound healing and scar reduction with prostaglandin ep4 agonist combinations |
| US10851412B2 (en) | 2013-03-15 | 2020-12-01 | Fate Therapeutics, Inc. | Cell potency assay for therapeutic potential |
| US9968716B2 (en) | 2013-10-15 | 2018-05-15 | Ono Pharmaceutical Co., Ltd. | Drug-eluting stent graft |
| US9763911B2 (en) * | 2013-12-12 | 2017-09-19 | Mayo Foundation For Medical Education And Research | Prostacyclin compositions for regulation of fracture repair and bone formation |
| US9918994B2 (en) | 2016-03-04 | 2018-03-20 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions and methods for muscle regeneration using prostaglandin E2 |
| JPWO2018124236A1 (ja) | 2016-12-27 | 2019-11-14 | 国立大学法人大阪大学 | 難治性心疾患治療用医薬組成物 |
| WO2018227138A1 (en) | 2017-06-09 | 2018-12-13 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions and methods for preventing or treating muscle conditions |
| US20200206309A1 (en) * | 2017-07-27 | 2020-07-02 | The Mclean Hospital Corporation | METHODS AND COMPOSITIONS RELATED TO THE TREATMENT OF NURR1- AND PPARy-MEDIATED CONDITIONS |
| EP3718537A4 (en) | 2017-11-27 | 2021-11-10 | Osaka University | DISEASE-SPECIFIC LIPOSOMAL FORMULATION |
| JP7233087B2 (ja) * | 2019-03-18 | 2023-03-06 | 公立大学法人横浜市立大学 | 抗動脈硬化剤 |
| JP7588773B2 (ja) | 2019-10-28 | 2024-11-25 | セイルテックス・インコーポレイテッド | グルタミン酸２ｂ受容体拮抗薬及びシグマ受容体作動薬の鎮咳薬としての使用 |
| US12042503B2 (en) | 2020-02-12 | 2024-07-23 | Cytoagents, Inc. | Compositions and methods for treating coronavirus infections |
| WO2021202708A1 (en) * | 2020-03-31 | 2021-10-07 | Ensysce Biosciences, Inc. | Methods for treating viral infections with nafamostat |
| KR20220040169A (ko) * | 2020-09-23 | 2022-03-30 | (주)아이엠디팜 | 나파모스타트 또는 이의 약제학적으로 허용가능한 염을 포함하는 경구투여용 제제 |
| GB202211232D0 (en) | 2022-08-02 | 2022-09-14 | Heptares Therapeutics Ltd | Prostaglandin EP4 receptor agonist compounds |
Family Cites Families (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE555319A (https=) | 1956-03-21 | 1900-01-01 | ||
| US3095355A (en) | 1961-10-12 | 1963-06-25 | Revlon | Aerosol composition |
| JPS503362B1 (https=) | 1970-06-10 | 1975-02-04 | ||
| JPS5231404B1 (https=) | 1971-04-28 | 1977-08-15 | ||
| US3965143A (en) | 1974-03-26 | 1976-06-22 | G. D. Searle & Co. | 16-Oxygenated prostanoic acid derivatives |
| US4132738A (en) | 1978-02-23 | 1979-01-02 | Miles Laboratories, Inc. | Preparation of 15-deoxy-16-hydroxyprostaglandins |
| IT1113341B (it) | 1978-03-31 | 1986-01-20 | Ono Pharmaceutical Co | Analoghi della 6,9-metano-pgi2 |
| JPS54130543A (en) * | 1978-03-31 | 1979-10-09 | Ono Pharmaceut Co Ltd | Prostagladin i2 analog, and its preparation |
| JPS57156460A (en) | 1981-03-20 | 1982-09-27 | Ono Pharmaceut Co Ltd | Stabilized composition of prostaglandin and prostaglandin mimic compound, and its preparation |
| US4650804A (en) | 1984-03-30 | 1987-03-17 | Fujisawa Pharmaceutical Co., Ltd. | Quinolizinone compounds and pharmaceutical composition comprising the same, useful as anti-ulcerative and anti-allergic agents |
| JPS6130519A (ja) | 1984-07-23 | 1986-02-12 | Dainippon Pharmaceut Co Ltd | 脳神経細胞の酸素欠乏性疾患治療剤 |
| JPS62134787A (ja) | 1985-12-06 | 1987-06-17 | 株式会社クボタ | 自動販売機の商品払出し装置 |
| KR100191137B1 (ko) * | 1992-07-21 | 1999-06-15 | 사노 가즈오 | 옥심 유도체 |
| US5462968A (en) | 1994-01-19 | 1995-10-31 | Allergan, Inc. | EP2 -receptor agonists as agents for lowering intraocular pressure |
| US5698598A (en) | 1995-08-04 | 1997-12-16 | Allergan | EP2 -receptor agonists as agents for lowering intraocular pressure |
| UA59384C2 (uk) | 1996-12-20 | 2003-09-15 | Пфайзер, Інк. | Похідні сульфонамідів та амідів як агоністи простагландину, фармацевтична композиція та способи лікування на їх основі |
| NO317155B1 (no) | 1997-02-04 | 2004-08-30 | Ono Pharmaceutical Co | <omega>-cykloalkyl-prostagladin-E<N>2</N>-derivater |
| JP3162668B2 (ja) | 1997-02-04 | 2001-05-08 | 小野薬品工業株式会社 | ω−シクロアルキル−プロスタグランジンＥ２誘導体 |
| KR20000070903A (ko) | 1997-02-10 | 2000-11-25 | 오노 야꾸힝 고교 가부시키가이샤 | 11,15-ｏ-디알킬프로스타글란딘 ｅ 유도체, 이것의 제조 방법 및 이것을 유효 성분으로 함유하는 약제 |
| AU7349298A (en) | 1997-06-23 | 1999-01-04 | Pfizer Inc. | Prostaglandin agonists |
| SE9702681D0 (sv) | 1997-07-10 | 1997-07-10 | Pharmacia & Upjohn Ab | Method and composition for treatment of impotence |
| KR20010023360A (ko) * | 1997-08-27 | 2001-03-26 | 미즈시마 유타카 | 혈관신생 촉진제 |
| US6124314A (en) | 1997-10-10 | 2000-09-26 | Pfizer Inc. | Osteoporosis compounds |
| UA67754C2 (uk) | 1997-10-10 | 2004-07-15 | Пфайзер, Інк. | Агоністи простагландину, фармацевтична композиція на їх основі (варіанти), спосіб нарощення та збереження кісткової маси у хребетних та спосіб лікування (варіанти) |
| US5877211A (en) * | 1997-11-21 | 1999-03-02 | Allergan | EP2 receptor agonists as neuroprotective agents for the eye |
| US6262293B1 (en) | 1997-12-25 | 2001-07-17 | Ono Pharmaceutical Co., Ltd. | ω-Cycloalkly-prostaglandin e2 derivatives |
| KR20010041358A (ko) | 1998-02-27 | 2001-05-15 | 우에노 도시오 | 표적 장기 이행성 담체 폴리머 및 약물 함유 폴리머 |
| JP4123568B2 (ja) | 1998-05-06 | 2008-07-23 | 小野薬品工業株式会社 | ６−オキソ−ｐｇｅ１化合物、それらの製造方法およびそれらを有効成分として含有するプロスタグランジンｅ２受容体作働薬 |
| TWI249520B (en) * | 1998-07-15 | 2006-02-21 | Ono Pharmaceutical Co | 5-Thia-omega-substituted phenyl prostaglandin E derivatives, method for producing the same and medicines containing the same as the active ingredient |
| US6235780B1 (en) | 1998-07-21 | 2001-05-22 | Ono Pharmaceutical Co., Ltd. | ω-cycloalkyl-prostaglandin E1 derivatives |
| JP2000086517A (ja) * | 1998-09-16 | 2000-03-28 | Ono Pharmaceut Co Ltd | アロディニア治療剤 |
| AUPP608898A0 (en) | 1998-09-23 | 1998-10-15 | Fujisawa Pharmaceutical Co., Ltd. | New use of prostaglandin E2 antagonists |
| US6437146B1 (en) | 1998-09-25 | 2002-08-20 | Fujisawa Pharmaceutical Co., Ltd. | Oxazole compounds as prostaglandin e2 agonists or antagonists |
| EP1121133A1 (en) | 1998-10-15 | 2001-08-08 | Merck & Co., Inc. | Methods for stimulating bone formation |
| JP2000239188A (ja) * | 1998-12-22 | 2000-09-05 | Mitsubishi Chemicals Corp | 育毛剤 |
| US6462080B1 (en) | 1998-12-24 | 2002-10-08 | Alcon Manufacturing, Ltd. | Prostaglandin E receptor agonists for treatment of dry eye |
| AU2211700A (en) | 1998-12-24 | 2000-07-31 | Alcon Laboratories, Inc. | Prostaglandin e agonists for treatment of glaucoma |
| AU2183900A (en) | 1998-12-24 | 2000-07-31 | Alcon Laboratories, Inc. | Ep4 receptor agonists for treatment of dry eye |
| SE9900025D0 (sv) | 1999-01-08 | 1999-01-08 | Synphora Ab | Method and composition for treatment of female sexual dysfunction |
| WO2000054808A1 (fr) | 1999-03-16 | 2000-09-21 | Toray Industries, Inc. | Agoniste du recepteur ep4 de la prostaglandine et traitement correspondant |
| CA2332375A1 (en) | 1999-03-16 | 2000-09-21 | Masafumi Isogaya | Cervical ripening agent and cervical ripening method |
| DE60012751T2 (de) | 1999-08-10 | 2005-01-20 | Glaxo Group Ltd., Greenford | Verwendung von EP 4 Rezeptorliganden zur Behandlung von neuropathischem Schmerz |
| AUPQ253199A0 (en) | 1999-08-30 | 1999-09-23 | Fujisawa Pharmaceutical Co., Ltd. | Non-prostanoid prostaglandin I2-agonist |
| GEP20043203B (en) | 1999-12-22 | 2004-03-25 | Pfizer Prod Inc | EP4 Receptor Selective Agonists in the Treatment of Osteoporosis |
| IL141120A0 (en) | 2000-01-31 | 2002-02-10 | Pfizer Prod Inc | Use of prostaglandin (pge2) receptor 4 (epa) selective agonists for the treatment of acute and chronic renal failure |
| US20010056060A1 (en) * | 2000-02-07 | 2001-12-27 | Cameron Kimberly O. | Treatment of osteoporsis with EP2/EP4 receptor selective agonists |
| CN1366458A (zh) * | 2000-03-31 | 2002-08-28 | 东丽株式会社 | 毛发生长和毛发形成调节剂 |
| FR2812190B1 (fr) | 2000-07-28 | 2003-01-31 | Oreal | Utilisation d'agonistes non prostanoiques des recepteurs des prostaglandines ep-2 et/ou ep-4 comme agent cosmetique permettant d'attenuer, de diminuer ou d'arreter la chute des cheveux et des poils |
| US6376533B1 (en) | 2000-10-20 | 2002-04-23 | Allergan Sales, Inc. | Omega-cycloalkyl 17-heteroaryl prostaglandin E2 analogs as EP2-receptor agonists |
| US20020161026A1 (en) | 2000-11-07 | 2002-10-31 | Paralkar Vishwas M. | Combination therapies for the stimulation of bone growth |
| OA12533A (en) | 2000-11-27 | 2006-06-05 | Pfizer Prod Inc | Ep4 receptor selective agonists in the treatment of osteoporosis. |
| GB0030541D0 (en) | 2000-12-14 | 2001-01-31 | Glaxo Group Ltd | Medical uses |
| GB0103269D0 (en) | 2001-02-09 | 2001-03-28 | Glaxo Group Ltd | Napthalene derivatives |
| US7410991B2 (en) | 2001-10-23 | 2008-08-12 | Laboratoires Serono S.A. | Pyrazolidinone compounds as ligands of the prostaglandin EP2 and/or EP4 receptors |
| DE60235198D1 (de) | 2001-12-20 | 2010-03-11 | Merck Serono Sa Coinsins | Pyrrolidin-derivatie als prostaglandin-modulatoren |
| ES2584606T3 (es) | 2002-10-10 | 2016-09-28 | Ono Pharmaceutical Co., Ltd. | Microesferas que comprenden ONO-1301 |
| ES2459743T3 (es) | 2006-10-19 | 2014-05-12 | Ono Pharmaceutical Co., Ltd. | Preparación de liberación sostenida para terapia de regeneración tisular |
-
2003
- 2003-10-09 ES ES11010286.0T patent/ES2584606T3/es not_active Expired - Lifetime
- 2003-10-09 US US10/530,685 patent/US7547715B2/en not_active Expired - Lifetime
- 2003-10-09 JP JP2005501023A patent/JP4497320B2/ja not_active Expired - Fee Related
- 2003-10-09 ES ES03754060T patent/ES2393321T3/es not_active Expired - Lifetime
- 2003-10-09 EP EP11010286.0A patent/EP2465537B1/en not_active Expired - Lifetime
- 2003-10-09 HU HUE11010286A patent/HUE029417T2/en unknown
- 2003-10-09 EP EP03754060A patent/EP1563846B1/en not_active Expired - Lifetime
- 2003-10-09 TW TW092128052A patent/TW200413000A/zh unknown
- 2003-10-09 DK DK03754060.6T patent/DK1563846T3/da active
- 2003-10-09 AU AU2003272963A patent/AU2003272963A1/en not_active Abandoned
- 2003-10-09 PT PT110102860T patent/PT2465537T/pt unknown
- 2003-10-09 DK DK11010286.0T patent/DK2465537T3/en active
- 2003-10-09 WO PCT/JP2003/012981 patent/WO2004032965A1/ja not_active Ceased
- 2003-10-09 PT PT03754060T patent/PT1563846E/pt unknown
-
2008
- 2008-02-20 US US12/034,614 patent/US8436026B2/en active Active
-
2010
- 2010-02-22 JP JP2010036052A patent/JP5287761B2/ja not_active Expired - Fee Related
-
2013
- 2013-04-04 US US13/856,538 patent/US8642630B2/en not_active Expired - Fee Related